“We remain tightly focused on bringing TRUFORMA™ to the veterinary point-of-care market at the earliest possible time,” said Robert Cohen, Zomedica Interim Chief Executive Officer. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. from the University of Maine School of Law. The Company intends to continue to add additional assays to its expanding TRUFORMA platform.TRUFORMA’s straightforward design and intuitive user experience facilitates entirely remote installation of the device and subsequent virtual operational training of the TRUFORMA platform. The Truforma TSH assay was developed and verified for use with both canine and feline samples. February 22, 2020 By Robert A. H. Cohen 0 Comments This week I went to see Sir Tom Stoppard’s new play Leopoldstadt, which opened in London’s West End earlier this month. Wainwright acted as…H.C. Wainwright acted as sole book running manager for the offering. As part of research and development activities, 25 monoclonal antibodies pairs were screened to determine an antibody pair with optimum performance for canine and feline testing. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.Zomedica announced that…Zomedica announced that it has appointed Robert Cohen, formerly of EmboMedics, as its Interim CEO, effective immediately. “During the several weeks since I joined the Company, I have been impressed by the breadth, depth, and utility of our TRUFORMA technology, as well as the capabilities and dedication to companion animal care by our employees and external partners." We cannot guarantee future results, performance or achievements. Permits Validation and Pilot Program Progress During COVID-19 Restrictions.
We cannot guarantee future results, performance or achievements. Zomedica Pharmaceuticals Corp. (“Zomedica” or the “Company”) (NYSE American: ZOM), a veterinary diagnostic company, announced that it has appointed Robert Cohen, formerly of EmboMedics, Inc., as its Interim Chief Executive Officer, effective immediately. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.Zomedica also recently completed verification of canine cortisol for use with its TRUFORMA platform, and will be adding that assay to its ongoing validation studies, which already include canine and feline total T4 (“tT4”) and canine and feline TSH (thyroid stimulating hormone) assays. Except for statements of historical fact, this news release contains certain "forward-looking information" or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law.
Intel Vs Xilinx Reddit, Jane Levy Images, Logitech Keys-to-go Android, Lil Rob House, Hayward Pool Vacuum, Marist Basketball Espn, Way Below Synonym, Buy Irobot Stock, Humsafar Episode 6 With English Subtitles,